These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16792685)

  • 21. Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles.
    Harcourt JL; Anderson LJ; Sullender W; Tripp RA
    Vaccine; 2004 Jun; 22(17-18):2248-60. PubMed ID: 15149784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.
    Mader D; Huang Y; Wang C; Fraser R; Issekutz AC; Stadnyk AW; Anderson R
    Vaccine; 2000 Jan; 18(11-12):1110-7. PubMed ID: 10590333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary T cells induced by respiratory syncytial virus are functional and can make an important contribution to long-lived protective immunity.
    Ostler T; Ehl S
    Eur J Immunol; 2002 Sep; 32(9):2562-9. PubMed ID: 12207340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus.
    Fu YH; He JS; Wang XB; Zheng XX; Wu Q; Xie C; Zhang M; Wei W; Tang Q; Song JD; Qu JG; Hong T
    Biochem Biophys Res Commun; 2010 Apr; 395(1):87-92. PubMed ID: 20350532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model.
    Cyr SL; Angers I; Guillot L; Stoica-Popescu I; Lussier M; Qureshi S; Burt DS; Ward BJ
    Vaccine; 2009 Jan; 27(3):421-30. PubMed ID: 19013492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR; Graham BS
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice.
    Jafri HS; Chavez-Bueno S; Mejias A; Gomez AM; Rios AM; Nassi SS; Yusuf M; Kapur P; Hardy RD; Hatfield J; Rogers BB; Krisher K; Ramilo O
    J Infect Dis; 2004 May; 189(10):1856-65. PubMed ID: 15122522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
    Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
    Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single amino acid substitution in a recombinant G protein vaccine drastically curtails protective immunity against respiratory syncytial virus (RSV).
    Huang Y; Anderson R
    Vaccine; 2003 Jun; 21(19-20):2500-5. PubMed ID: 12744884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination.
    Helson R; Olszewska W; Singh M; Megede JZ; Melero JA; O'Hagan D; Openshaw PJ
    Vaccine; 2008 Feb; 26(6):753-61. PubMed ID: 18191308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.
    Mottram PL; Leong D; Crimeen-Irwin B; Gloster S; Xiang SD; Meanger J; Ghildyal R; Vardaxis N; Plebanski M
    Mol Pharm; 2007; 4(1):73-84. PubMed ID: 17274665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies.
    Voges B; Vallbracht S; Zimmer G; Bossow S; Neubert WJ; Richter K; Hobeika E; Herrler G; Ehl S
    Cell Immunol; 2007 Jun; 247(2):85-94. PubMed ID: 17904538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection.
    Cautivo KM; Bueno SM; Cortes CM; Wozniak A; Riedel CA; Kalergis AM
    J Immunol; 2010 Dec; 185(12):7633-45. PubMed ID: 21084664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alveolar macrophages support interferon gamma-mediated viral clearance in RSV-infected neonatal mice.
    Eichinger KM; Egaña L; Orend JG; Resetar E; Anderson KB; Patel R; Empey KM
    Respir Res; 2015 Oct; 16():122. PubMed ID: 26438053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultrafine carbon black particles enhance respiratory syncytial virus-induced airway reactivity, pulmonary inflammation, and chemokine expression.
    Lambert AL; Mangum JB; DeLorme MP; Everitt JI
    Toxicol Sci; 2003 Apr; 72(2):339-46. PubMed ID: 12655033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.
    Elliott MB; Pryharski KS; Yu Q; Boutilier LA; Campeol N; Melville K; Laughlin TS; Gupta CK; Lerch RA; Randolph VB; LaPierre NA; Dack KM; Hancock GE
    J Virol; 2004 Aug; 78(16):8446-54. PubMed ID: 15280453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of repeated respiratory syncytial virus infections on pulmonary dendritic cells in a murine model of allergic asthma.
    Hirose H; Matsuse H; Fukahori S; Tsuchida T; Tomari S; Kawano T; Fukushima C; Mizuta Y; Kohno S
    Int Arch Allergy Immunol; 2008; 147(3):197-205. PubMed ID: 18594149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
    Bukreyev A; Belyakov IM; Prince GA; Yim KC; Harris KK; Berzofsky JA; Collins PL
    J Virol; 2005 Aug; 79(15):9515-26. PubMed ID: 16014914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1β Responses.
    Russell RF; McDonald JU; Ivanova M; Zhong Z; Bukreyev A; Tregoning JS
    J Virol; 2015 Sep; 89(17):8974-81. PubMed ID: 26085154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of preexposure to ultrafine carbon black on respiratory syncytial virus infection in mice.
    Lambert AL; Trasti FS; Mangum JB; Everitt JI
    Toxicol Sci; 2003 Apr; 72(2):331-8. PubMed ID: 12660365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.